Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT07055516

Public ClinicalTrials.gov record NCT07055516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 6 months treatment period.

Study identification

NCT ID
NCT07055516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NodThera Limited
Industry
Enrollment
176 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 7, 2025
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update posted
Jun 29, 2026

2025 – 2026

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
Investigative site Mesa Arizona 85225
Investigative site Los Angeles California 90057
Investigative site Cooper City Florida 33024
Investigative Site Hialeah Florida 33016
Investigative Site Jacksonville Florida 32216
Investigative Site Miami Florida 33147
Investigative Site Port Orange Florida 32127
Investigative Sites Marrero Louisiana 70006
Investigative Site Columbus Ohio 43213
Investigative Site Dallas Texas 75230
Investigative Site Manassas Virginia 20110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07055516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07055516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →